Activation of Platelets in Platelet-Rich Plasma by Rotablation Is Speed-Dependent and Can Be Inhibited by Abciximab (c7E3 Fab; ReoPro)
Authors:
- 25 August 1998
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (8) , 742-748
Abstract
Background —Rotational atherectomy with the Rotablator catheter has improved percutaneous treatment of certain coronary atherosclerotic lesions, but the “no-reflow” phenomenon remains a serious complication. Because platelet activation by rotablation may contribute to the no-reflow phenomenon, we developed an in vitro system to test the effect of rotablation on platelets in the absence or presence of platelet GP IIb/IIIa receptor blockade with abciximab. Methods and Results —Platelet-rich plasma (PRP) was prepared from 28 healthy human volunteers. PRP was divided into 4 samples: (1) no treatment, (2) 6D1 (anti–GP Ib), (3) c7E3 Fab (anti–GP IIb/IIIa+α v β 3 ), and (4) c7E3 Fab+6D1. Samples were pumped through a flow chamber containing a 2.5-mm burr rotating at various speeds and then placed in an aggregometer. PRP samples tested in the absence of antibody underwent more rapid and extensive aggregation when rotablated at 150 000 and 180 000 rpm compared with 0 rpm ( P P =0.09 for 70 000 and P 0.5, P =0.99, and P =0.091 for 70 000, 150 000, and 180 000 rpm). Platelet ATP release, a marker of granule release and cell damage, was markedly increased at 180 000 rpm ( P =0.002 compared with 0 rpm in the control group). Electron microscopy revealed extensive rotablation-induced platelet damage at 150 000 and 180 000 rpm, and leakage of LDH confirmed platelet lysis at these speeds ( P =0.002 and P Conclusions —High-speed rotablation induces platelet activation of PRP, leading to aggregation; pretreating PRP with abciximab decreases the aggregation. These data suggest that pretreatment of patients with abciximab may decrease rotablation-induced platelet aggregation during rotational atherectomy.Keywords
This publication has 14 references indexed in Scilit:
- Networking in the Hemostatic SystemJournal of Biological Chemistry, 1997
- Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".Journal of Clinical Investigation, 1996
- Clinical and Postmortem Outcome of ‘No–Reflow’ Phenomenon in a Patient Treated With Rotational AtherectomySouthern Medical Journal, 1996
- Effects of technique modification on immediate results of high speed rotational atherectomy in 710 procedures on 656 patientsCatheterization and Cardiovascular Diagnosis, 1995
- Characterization of the Unique Mechanism Mediating the Shear-dependent Binding of Soluble von Willebrand Factor to PlateletsJournal of Biological Chemistry, 1995
- High speed rotational atherectomy: Outcome in calcified and noncalcified coronary artery lesionsJACC, 1995
- Rotational AblationCardiology Clinics, 1994
- Doppler Flow Velocity Measurements During Coronary AngioplastyAngiology, 1994
- Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.Journal of Clinical Investigation, 1986
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.Journal of Clinical Investigation, 1985